Ultragenyx Pharmaceutical (RARE) News Today → 4 Cryptos BETTER than Bitcoin (From True Market Insiders) (Ad) Free RARE Stock Alerts $39.34 -1.00 (-2.48%) (As of 05/28/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 29 at 3:41 AM | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesUltragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the twelve brokerages that are covering the firm, Marketbeat reports. One analyst has rated the stock with a hold recommendation and eleven have issued a buy recommendationMay 26 at 7:12 AM | marketbeat.comTrexquant Investment LP Boosts Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Trexquant Investment LP grew its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 81.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 53,500 shares of the biopharmaceutical company's stock afterMay 25, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Purchases 75,100 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Charles Schwab Investment Management Inc. raised its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 18.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 471,825 shMay 23, 2024 | benzinga.comUltragenyx Pharmaceutical Stock (NASDAQ:RARE), Quotes and News SummaryMay 22, 2024 | finance.yahoo.comUltragenyx Faces Lawsuit Over Alleged Unjust Use of Henrietta Lacks' CellsMay 22, 2024 | marketbeat.comGreat Lakes Advisors LLC Decreases Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Great Lakes Advisors LLC lessened its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 49.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 27,773 shares of the biopharmaceutical comMay 21, 2024 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Purchased by Clearbridge Investments LLCClearbridge Investments LLC lifted its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 3.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,383,492 shares of the biopharmaceutical cMay 19, 2024 | marketbeat.comBNP Paribas Financial Markets Trims Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)BNP Paribas Financial Markets cut its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 26.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 157,281 shares of the biopharmaceMay 17, 2024 | globenewswire.comUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 13, 2024 | markets.businessinsider.comBuy Rating Affirmed: Ultragenyx’s Gene Therapy Shows Promising Efficacy and Safety ProfilesMay 8, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Hologic (HOLX) and Arbutus Biopharma (ABUS)May 7, 2024 | finance.yahoo.comUltragenyx to Participate at Bank of America’s 2024 Healthcare ConferenceMay 6, 2024 | marketbeat.comUltragenyx Pharmaceutical (NASDAQ:RARE) Price Target Lowered to $109.00 at Canaccord Genuity GroupCanaccord Genuity Group cut their target price on Ultragenyx Pharmaceutical from $111.00 to $109.00 and set a "buy" rating for the company in a research note on Monday.May 6, 2024 | marketbeat.comNew York State Common Retirement Fund Has $3.48 Million Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)New York State Common Retirement Fund grew its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 37.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 72,866 shares of the biopharmaMay 4, 2024 | finance.yahoo.comHere's What Analysts Are Forecasting For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) After Its First-Quarter ResultsMay 4, 2024 | insidermonkey.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2024 Earnings Call TranscriptMay 4, 2024 | markets.businessinsider.comTruist Financial Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)May 3, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Amgen (AMGN) and Zimmer Biomet Holdings (ZBH)May 3, 2024 | markets.businessinsider.comWedbush Reaffirms Their Hold Rating on Ultragenyx Pharmaceutical (RARE)May 3, 2024 | finance.yahoo.comUltragenyx Pharmaceutical Inc (RARE) (Q1 2024) Earnings Call Transcript Highlights: Key ...May 3, 2024 | marketbeat.comUltragenyx Pharmaceutical (NASDAQ:RARE) Releases Quarterly Earnings Results, Misses Estimates By $0.31 EPSUltragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($2.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.72) by ($0.31). The business had revenue of $108.83 million for the quarter, compared to analysts' expectations of $116.03 million. Ultragenyx Pharmaceutical had a negative net margin of 139.70% and a negative return on equity of 369.54%. The firm's revenue for the quarter was up 8.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($2.33) EPS.May 3, 2024 | marketbeat.comCantor Fitzgerald Reiterates "Overweight" Rating for Ultragenyx Pharmaceutical (NASDAQ:RARE)Cantor Fitzgerald reiterated an "overweight" rating and issued a $107.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Friday.May 3, 2024 | marketbeat.comWedbush Cuts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $47.00Wedbush cut their price target on Ultragenyx Pharmaceutical from $48.00 to $47.00 and set a "neutral" rating for the company in a report on Friday.May 2, 2024 | sfgate.comUltragenyx: Q1 Earnings SnapshotMay 2, 2024 | msn.comUltragenyx Pharmaceutical GAAP EPS of -$2.03 misses by $0.28, revenue of $108.8M misses by $7.64MMay 2, 2024 | investorplace.comRARE Stock Earnings: Ultragenyx Pharmaceutical Misses EPS, Misses Revenue for Q1 2024May 2, 2024 | globenewswire.comUltragenyx Reports First Quarter 2024 Financial Results and Corporate UpdateApril 30, 2024 | globenewswire.comUltragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare DiseaseApril 30, 2024 | markets.businessinsider.comUltragenyx Pharmaceutical: Strong Buy Rating on Growth Prospects and Pipeline PotentialApril 30, 2024 | finance.yahoo.comUltragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)April 27, 2024 | marketbeat.com141,117 Shares in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Acquired by abrdn plcabrdn plc bought a new stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 141,117 shares of the biopharmaceutical company's stock, valued at approximately $6,748,0April 26, 2024 | marketbeat.comUltragenyx Pharmaceutical (RARE) to Release Quarterly Earnings on ThursdayUltragenyx Pharmaceutical (NASDAQ:RARE) will be releasing earnings after the market closes on Thursday, May 2, Zacks reports.April 25, 2024 | globenewswire.comUltragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate UpdateApril 24, 2024 | nasdaq.comFirst Week of RARE June 21st Options TradingApril 24, 2024 | marketbeat.comUltragenyx Pharmaceutical (NASDAQ:RARE) Price Target Raised to $61.00 at TD CowenTD Cowen upped their price target on shares of Ultragenyx Pharmaceutical from $59.00 to $61.00 and gave the stock a "buy" rating in a research report on Wednesday.April 23, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Ultragenyx Pharmaceutical (RARE)April 22, 2024 | markets.businessinsider.comForecasting The Future: 11 Analyst Projections For Ultragenyx PharmaceuticalApril 22, 2024 | marketbeat.comUltragenyx Pharmaceutical (NASDAQ:RARE) Receives New Coverage from Analysts at Royal Bank of CanadaRoyal Bank of Canada initiated coverage on shares of Ultragenyx Pharmaceutical in a report on Monday. They issued an "outperform" rating and a $77.00 price target on the stock.April 19, 2024 | globenewswire.comUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 18, 2024 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Holdings Raised by Federated Hermes Inc.Federated Hermes Inc. lifted its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 11.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,446,500 shares of the biopharmaceApril 18, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Accolade (ACCD), Ultragenyx Pharmaceutical (RARE) and Bristol-Myers Squibb (BMY)April 16, 2024 | marketbeat.comUltragenyx Pharmaceutical (NASDAQ:RARE) Trading Up 1.9%Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Up 1.9%April 16, 2024 | marketbeat.comWedbush Reiterates Neutral Rating for Ultragenyx Pharmaceutical (NASDAQ:RARE)Wedbush reiterated a "neutral" rating and issued a $48.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Tuesday.April 16, 2024 | marketbeat.comMirae Asset Global Investments Co. Ltd. Has $5.18 Million Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Mirae Asset Global Investments Co. Ltd. decreased its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 48.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 108,355 shareApril 15, 2024 | msn.comWhy Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day SessionApril 15, 2024 | marketbeat.comUltragenyx Pharmaceutical (NASDAQ:RARE) Shares Gap Down to $47.00Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Gap Down to $47.00April 15, 2024 | markets.businessinsider.comUltragenyx Reports Positive Interim Phase 1/2 Data With GTX-102 - Quick FactsApril 15, 2024 | finance.yahoo.comUltragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102April 12, 2024 | globenewswire.comUltragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman SyndromeApril 12, 2024 | finanznachrichten.deUltragenyx Pharmaceutical Inc.: Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting Get Ultragenyx Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter. Email Address 4 Cryptos BETTER than Bitcoin (Ad)Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than Bitcoin Click For My #1 FREE Crypto for 2024 RARE Media Mentions By Week RARE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RARE News Sentiment▼1.010.81▲Average Medical News Sentiment RARE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RARE Articles This Week▼74▲RARE Articles Average Week Get Ultragenyx Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Biohaven News HUTCHMED News Prestige Consumer Healthcare News Arrowhead Pharmaceuticals News IDEAYA Biosciences News Insmed News Summit Therapeutics News Axsome Therapeutics News Corcept Therapeutics News PTC Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RARE) was last updated on 5/29/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 Media4 Cryptos BETTER than BitcoinTrue Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsA once-in-a-century investment opportunityStansberry ResearchWrite this ticker symbol down…StocksToTradeMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemWeiss RatingsTop 5 AI Stocks to Buy for 2024Market Moving Trends Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.